FDA Approves Third Drug in BD Simplist Prefilled Injectable Line of Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Approves Third Drug in BD Simplist Prefilled Injectable Line of Products



BD Rx, a subsidiary of BD, reports that FDA has approved a third drug to be offered in the BD Simplist line of prefilled generic injectables. The third BD Simplist product to launch is ondansetron injection, US Pharmacopeia (USP) 4 mg/2 mL (2mg/mL), an injectable antiemetic.

Ondansetron injection, which is used to prevent postoperative nausea and vomiting, is currently on the FDA drug shortage list due to recent demand increases and supply issues faced by other manufacturers. The product can be used with initial and repeat courses of emetogenic cancer chemotherapy.

In March, BD announced that it would be manufacturing generic pharmaceutical products for the first time through it subsidiary BD Rx. BD Rx also manufactures metoclopramide injection, and diphenhydramine hydrochloride Injection, USP within the BD Simplist prefilled injectables line of products. BD Simplist prefilled injectables are designed to decrease the number of steps in the traditional vial and syringe injection sequence, thereby reducing the potential risk of medication error.

BD Rx plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses most commonly relied on by clinicians in both the hospital and surgical center settings.

Source: BD Rx

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here